/PRNewswire/ Cordis, a global interventional vascular technology company, today announced that Matthew Muscari will assume the role of President of the.
swirling around picking up the warmth all the tropics but as the weather pushes his words, the colder air comes of the sunshine towards the end of the week. that is a few days away and with that motor air even more milder and starting to push its way in. cordis conditions will be in the parts of east anglia and subsystem the mittens were roots of the clear skies seven or 8 but the routines in the west but will see the clout they can with the bricks of rain in the morning. during rush hour sprint was northern ireland through the morning and dwells in southwest england, heavy at times in that room will be happy at times in that room will be happy at times in that room will be happy at times and pushed eastwards, some just about staying dry and breading in the west later and after the morning sunshine, east anglia will be the end of the afternoon with the rain starting to develop your. some of which will be heavy in the channel islands stop temperatures across the country will be around 1
"Sense viure el món municipal, es pot estar molt desconnectat de la realitat" "Defensaré els micropobles perquè ocupen el 35% del territori de Catalunya"
is about our collective security in the indo-pacific region. so with total denuclearization is our objective. and remains so. i get the next question, huh? i like to ask the press a question. [laughter] nancy cordis, cbs. thank you very much, mr. president. i have one question about north korea and one question about israel. we change one question thing haven t we? two foreign policy questions. you have said in the past that you would not meet with kim jong united auto workers union the leader of north korea without certain preconditions. yes. what are those preconditions and do you believe he would ever be able to meet them? well, what i never do is i never make a judgment with a man what a man or woman is going to do or not do based on what they
Pherecydes Pharma s Phage Production Project (PhagoPROD) Featured in the European Commission s CORDIS Magazine
Regulatory News:
Pherecydes Pharma (FR0011651694 ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that its PhagoPROD project, partly funded by the European Commission, has been featured in CORBIS magazine. To read the article, please click on this link
CORBIS is the European Commission magazine highlighting the most strategic Research and Development projects financed by the European Union (EU).
PhagoPROD is one of the elements of Pherecydes Pharma s development that benefits from Horizon 20/20 funding enabling the Company to implement all the production procedures required to produce phages in accordance with Good Manufacturing Practices (GMP). These high pharmaceutical quality phages are necessary to launch clinical trials and make them available to medica